Physician profile
Daniel Demesh
NPI 1629485586
$6,374.60
in general payments reported to CMS, 2019-2025
9 companies · $625 in 2025
The $625 reported for 2025 was more than what 76% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $223 · 2021: $172 · 2022: $1,141 · 2023: $3,425 · 2024: $602 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,270 · Travel and Lodging: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,270.39 |
| Travel and Lodging | $1,381.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,916.62 | 2020-2025 | Scopis Ent, Clarifix Cryotherapy Device |
| Aerin Medical INC. | $2,494.94 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $333.06 | 2023-2025 | Dupixent |
| Intersect Ent, INC. | $206.08 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $186.69 | 2019 | |
| Genzyme Corporation | $137.37 | 2024 | |
| Glaxosmithkline, LLC. | $66.26 | 2023 | Trelegy Ellipta, Arexvy |
| Myriad Genetic Laboratories, INC. | $18.75 | 2023 | Prolaris |
| Astellas Pharma US INC | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Demesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.